



Cherney et al. Cardiovascular Diabetology 2014, 13:28
http://www.cardiab.com/content/13/1/28ORIGINAL INVESTIGATION Open AccessThe effect of empagliflozin on arterial stiffness
and heart rate variability in subjects with
uncomplicated type 1 diabetes mellitus
David ZI Cherney1*, Bruce A Perkins2, Nima Soleymanlou3, Ronnie Har1, Nora Fagan4, Odd Erik Johansen5,
Hans-Juergen Woerle5, Maximilian von Eynatten4 and Uli C Broedl5Abstract
Background: Individuals with type 1 diabetes mellitus are at high risk for the development of hypertension,
contributing to cardiovascular complications. Hyperglycaemia-mediated neurohormonal activation increases arterial
stiffness, and is an important contributing factor for hypertension. Since the sodium glucose cotransport-2 (SGLT2)
inhibitor empagliflozin lowers blood pressure and HbA1c in type 1 diabetes mellitus, we hypothesized that this
agent would also reduce arterial stiffness and markers of sympathetic nervous system activity.
Methods: Blood pressure, arterial stiffness, heart rate variability (HRV) and circulating adrenergic mediators were
measured during clamped euglycaemia (blood glucose 4–6 mmol/L) and hyperglycaemia (blood glucose 9–11 mmol/L)
in 40 normotensive type 1 diabetes mellitus patients. Studies were repeated after 8 weeks of empagliflozin
(25 mg once daily).
Results: In response to empagliflozin during clamped euglycaemia, systolic blood pressure (111 ± 9 to 109 ± 9
mmHg, p = 0.02) and augmentation indices at the radial (−52% ± 16 to −57% ± 17, p = 0.0001), carotid (+1.3 ± 1
7.0 to −5.7 ± 17.0%, p < 0.0001) and aortic positions (+0.1 ± 13.4 to −6.2 ± 14.3%, p < 0.0001) declined. Similar
effects on arterial stiffness were observed during clamped hyperglycaemia without changing blood pressure
under this condition. Carotid-radial pulse wave velocity decreased significantly under both glycemic conditions
(p ≤ 0.0001), while declines in carotid-femoral pulse wave velocity were only significant during clamped
hyperglycaemia (5.7 ± 1.1 to 5.2 ± 0.9 m/s, p = 0.0017). HRV, plasma noradrenalin and adrenaline remained
unchanged under both clamped euglycemic and hyperglycemic conditions.
Conclusions: Empagliflozin is associated with a decline in arterial stiffness in young type 1 diabetes mellitus
subjects. The underlying mechanisms may relate to pleiotropic actions of SGLT2 inhibition, including glucose
lowering, antihypertensive and weight reduction effects.
Trial registration: Clinical trial registration: NCT01392560
Keywords: Diabetes mellitus, Systemic blood pressure, SGLT2 inhibition, Empagliflozin, Hyperglycaemia,
Arterial stiffness, Heart rate variability* Correspondence: david.cherney@uhn.on.ca
1Division of Nephrology, University Health Network, University of Toronto,
Toronto General Hospital, 585 University Ave, Toronto 8N-845, M5G 2N2,
Ontario, Canada
Full list of author information is available at the end of the article
© 2014 Cherney et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
stated.
Cherney et al. Cardiovascular Diabetology 2014, 13:28 Page 2 of 8
http://www.cardiab.com/content/13/1/28Background
In type 2 diabetes mellitus (T2D), approximately 40% of
patients are hypertensive at the time of diagnosis, and in
type 1 DM (T1D), the prevalence of hypertension in-
creases with longer duration of disease [1]. Hypergly-
caemia plays a critical role in the pathogenesis of diabetic
complications and in the development of hypertension in
patients with DM. This is explained in part through effects
on activation of the renin angiotensin aldosterone system
(RAAS) and sympathetic nervous system (SNS) as well as
suppression of nitric oxide [2], leading to macrovascular
dysfunction including increased arterial stiffness [3]. To-
gether with changes in arterial structure secondary to
long-standing DM, hyperglycaemia-mediated neurohor-
monal activation increases vascular tone and arterial
stiffness, thereby raising the risk of hypertension [4,5].
Unfortunately, blockade of RAAS pathways provides in-
complete protection against the development of diabetic
complications [6] and dual RAAS blockade strategies may
increase the risk of serious adverse effects such as acute
kidney injury and hyperkalemia [7,8]. The development of
safe, new agents that augment vascular protection in pa-
tients with DM is therefore of the utmost importance.
Aside from effects of RAAS and SNS activation on
vascular function, arterial stiffness increases under the
influence of ambient hyperglycaemia and can be im-
proved through tight glycemic control [9-11]. Intensifi-
cation of glycemic control in both T1D and T2D reduces
arterial stiffness, which may contribute to improved blood
pressure control and a decreased risk of cardiovascular

















Figure 1 Physiological mechanisms implicated in arterial stiffness lowlowering strategies also increase the risk of severe
hypoglycemic events [15-17] and promote weight gain
and sodium retention resulting in higher blood pressure
[16-18], thereby mitigating the benefit that can be
achieved through tight glycemic control [19].
Alternatively, glucose lowering may be achieved with
novel sodium glucose co-transport 2 (SGLT2) inhibitors
in patients with T2D [20,21]. Since these agents lower
blood glucose through insulin-independent increases in
urinary glucose excretion, SGLT2 inhibition has also been
used in T1D patients, and improves glycemic control
[22,23]. In addition to having a low risk of hypoglycaemia,
this class of oral hypoglycemic agents induces clinically
relevant and sustained weight loss and declines in blood
pressure in patients with T1D [22,24] and T2D [20,25].
The blood pressure lowering effect of SGLT2 inhibition
may be related to several mechanisms, including diuretic
effects, changes in neurohormonal activation, improved
glycemic control and decreases in body weight (Figure 1).
Despite these pleiotropic effects, mechanistic human data
related to antihypertensive effects of these agents remain
limited. A thorough understanding of the blood pressure
lowering effects of SGLT2 inhibition is important, since
long-term cardiovascular outcome trials are underway,
and human mechanistic data may help to interpret the re-
sults of these clinical trials.
In a trial designed with the primary objective of investi-
gating renal hemodynamic effects of SGLT2 inhibition, we
examined systemic hemodynamic effects of empagliflozin
(Boehringer Ingelheim, Ingelheim, Germany), a new and
















ering effects with sodium glucose cotransport-2 inhibition.
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augmentation index and pulse wave velocity, leading to de-
clines in systemic blood pressure. In addition, due to the
stimulatory effect of hyperglycaemia on the SNS [26], we
hypothesized that empagliflozin would reduce neurohor-
monal activation, leading to improved heart rate variability
(HRV) and a decline in plasma adrenaline and noradrenalin.
Methods
Subjects
In this 8-week, open-label, prospective clinical trial, 42 par-
ticipants with T1D were treated with empagliflozin 25 mg
once daily (NCT01392560). Inclusion and exclusion cri-
teria at screening have been described elsewhere [24]
(http://www.clinicaltrials.gov/ct2/show/NCT01392560). In
brief, men and women ≥18 years with T1D ≥ 12 months
with estimated GFR ≥60 ml/min/1.73 m2 and no hyperten-
sion or macroalbuminuria were included. Patients taking
medication known to interfere with RAAS activity and/or
renal function based on investigator judgment were ex-
cluded [24]. Of note, none of the patients were taking med-
ications that can affect arterial stiffness or blood pressure,
such as renin angiotensin aldosterone system blockers,
beta blockers, calcium channel blockers, diuretics or other
antihypertensive agents. Two cases of diabetic ketoacidosis
leading to discontinuation occurred during the study: one
in the context of insulin pump failure and the other in the
setting of acute gastroenteritis. These patients were with-
drawn within the first 3 days of drug exposure and were in-
cluded only in the safety analyses. Detailed data regarding
other adverse effects of empagliflozin in this cohort have
been reported elsewhere [24]. 40 subjects completed the
study (Table 1) and the primary endpoint of change in
renal function in response to empagliflozin has been re-
ported elsewhere [24]. In this manuscript we report the
pre-specified exploratory vascular endpoint results. TheTable 1 Baseline Clinical Characteristics of the 40 Patients
with Type 1 Diabetes
Male sex (%) 20 (50%)
Age (yr – mean ± SD) 24.3 ± 5.1
Diabetes Duration (yr)
>1-5 years – n (%) 4 (10)
>5 years – n (%) 36 (90)
Current Smoking - n (%) 4 (10)
Presence of Non-Proliferative Retinopathy - n (%) 0
Body mass index (kg/m2) 24.5 ± 3.2
HbA1C (%) 8.0 ± 0.9
Urine albumin/creatinine ratio (mg/mmol) 1.2 ± 0.9
Urine albumin/creatinine ratio reported is the average of the baseline values
that were collected during clamped euglycemia and hyperglycemia. Urinary
albumin concentration was determined by immunoturbidimetry and HbA1C
was measured by high-performance liquid chromatography [27].Research Ethics Board at the University Health Network
(Toronto, Canada) approved the protocol and all subjects
gave informed consent prior to start of study procedures.
The study was conducted according to the International
Conference on Harmonization on Good Clinical Practice.
Experimental design
Subjects adhered to a sodium-replete and moderate protein
diet during the 7-day period before each experiment, as de-
scribed previously [27]. After admission to the Renal Physi-
ology Laboratory, euglycemic (4–6 mmol/L) conditions on
the first day, followed by hyperglycemic (9–11 mmol/L)
conditions on the second day, were maintained by a modi-
fied glucose clamp technique. Studies were performed on
two consecutive days at baseline after maintenance of the
clamp within the desired range for approximately 5 hours
preceding and during all investigations, as described
previously [24].
Following the glucose clamp, right radial artery and ca-
rotid waveforms were recorded with a high-fidelity micro-
manometer and using the validated transfer function,
corresponding central aortic pressure waveform data were
generated (SPC-301, Millar Instruments SphygmoCor,
AtCor Medical Systems Inc., Sydney, Australia). Augmen-
tation index, an estimate of systemic arterial stiffness was
calculated as the difference between the second systolic
peak and inflection point, expressed as a percentage of the
central pulse pressure corrected to an average heart rate of
75 beats per minute. The aortic pulse wave velocity
(PWV) was measured using the same device by sequen-
tially recording ECG-gated right carotid and radial artery
waveforms. Two vascular measurements were obtained for
each parameter and the average value reported. The use of
the SphygmoCor device to assess arterial stiffness parame-
ters has been previously published by our group [28]. Au-
tomated blood pressure measurements were obtained
using a DINAMAP machine (Critikon, Tampa, Florida)
and the average of two values obtained immediately prior
to the arterial stiffness assessments are reported.
After completion of arterial stiffness testing, HRV test-
ing was performed using AtCor software (Atcor Medical
Systems Inc., Sydney, Australia). In brief, two 10-minute
segments were recorded. Vagal tone (Root Mean Square
Successive Difference - RMSSD) and sympathetic activ-
ity (Standard Deviation of Normal-to-Normal interval -
SDNN) measures were obtained at each of the two
periods and the results were then averaged. Plasma nor-
adrenalin and adrenaline concentrations were obtained
on each of the study days according to standard, previ-
ously described methods [29].
Statistical analysis
The primary endpoint of this study was change in GFR
after treatment with empagliflozin for 8 weeks [24].
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changes in GFR [24]. Accordingly, results reported in
this manuscript were pre-specified, exploratory end-
points. Paired t-tests were performed to evaluate differ-
ences in vascular measurements and neurohormonal
outcomes before and after treatment with empagliflozin.
A repeated measures model was used to evaluate differ-
ences in response to empagliflozin between euglycemic
and hyperglycemic conditions. All statistical analyses were
performed using the statistical package SAS (Version 9.2).
Results
Baseline demographic parameters
The baseline characteristics of this T1D study cohort are
described in Table 1. This cohort comprised a mainly
young group of participants with uncomplicated T1D
that has been described in more detail elsewhere [22,24].
All except for 4 patients (ages 31, 33, 34 and 44 years
old) were between the ages of 18–30.
Effects of empagliflozin on blood pressure, arterial
stiffness and heart rate variability during clamped
euglycaemia
During clamped euglycaemia, empagliflozin significantly
reduced systolic blood pressure, radial augmentation
index, carotid augmentation index and aortic augmenta-
tion index (Table 2, Figure 2). Carotid-radial pulse wave
velocity decreased significantly (p = 0.0001), while similar
trends for carotid-femoral pulse wave velocity were not
significant. Effects on vagal tone (RMSSD) and SNS
activity (SDNN, plasma noradrenalin and adrenaline)
were not significant.Table 2 Hemodynamic responses to empagliflozin in patients




Systolic blood pressure (mmHg) 111.2 ± 8.9 108.5 ± 8.
Diastolic blood pressure (mmHg) 63.6 ± 8.5 63.1 ± 8.1
Pulse (beats per minute) 74.2 ± 13.1 71.8 ± 13.
Vascular parameters
Radial augmentation index (%) −52.0 ± 16.1 −57.0 ± 16
Carotid radial pulse wave velocity (m/s) 7.3 ± 1.1 6.7 ± 0.9
Carotid femoral pulse wave velocity (m/s) 5.5 ± 0.9 5.3 ± 1.0
Heart rate variability
RMSSD (milliseconds) 46.3 ± 22.9 53.6 ± 32.
SDNN (milliseconds) 69.3 ± 24.0 73.8 ± 33.
Biochemistry
Plasma adrenaline (nmol/L) 0.13 ± 0.07 0.12 ± 0.0
Plasma nordrenaline (nmol/L) 0.75 ± 0.35 0.76 ± 0.3Effects of empagliflozin on blood pressure, arterial
stiffness and heart rate variability during clamped
hyperglycaemia
During clamped hyperglycemic conditions, treatment
with empagliflozin did not reduce blood pressure signifi-
cantly, despite significant effects on radial augmentation
index, carotid augmentation index and aortic augmenta-
tion index (Table 2, Figure 2). Empagliflozin decreased
both carotid-radial and carotid-femoral pulse wave vel-
ocity under clamped hyperglycemic conditions (Table 2).
Similar to effects during clamped euglycemic conditions,
effects on SNS function including RMSSD, SDNN, plasma
noradrenalin and adrenaline, were not significant (Table 2,
Figure 2). In the repeated measures model used to evalu-
ate differences in response to empagliflozin between gly-
cemic conditions, there were no significant differences in
any of the hemodynamic parameters (p > 0.05, data not
shown).
Discussion
Despite optimal medical therapy including RAAS inhibi-
tors, many patients continue to develop hypertension,
chronic kidney disease and cardiovascular diseases [6].
Moreover, in T1D, primary prevention strategies with
RAAS blockers are ineffective [7]. Intensive glucose low-
ering therapies exert long lasting renal and cardiovascu-
lar protective effects, highlighting the need for improved
glucose control in patients with T1D and T2D [30-32].
Due to their unique insulin-independent mechanism of ac-
tion, SGLT2 inhibitors lower blood pressure and improve
glycemic control, while at the same time avoiding potential
risks of increased insulin doses such as hypoglycaemia,with type 1 diabetes during clamped euglycemia and
a Hyperglycemia
ozin p-value Baseline Empagliflozin p-value
7 0.02 112.1 ± 9.8 110.6 ± 9.8 0.2797
0.6191 65.2 ± 8.3 63.8 ± 7.3 0.2497
8 0.1885 72.0 ± 11.0 70.8 ± 12.8 0.4919
.7 0.0001 −47.9 ± 17.3 −52.1 ± 17.6 0.0190
0.0001 7.9 ± 1.1 6.9 ± 0.9 <0.0001
0.1366 5.7 ± 1.1 5.2 ± 0.9 0.0017
1 0.1050 58.0 ± 35.1 63.3 ± 37.7 0.3004
2 0.3278 77.7 ± 32.8 83.4 ± 32.2 0.2837
6 0.2946 0.13 ± 0.09 0.12 ± 0.06 0.1097






























































Figure 2 The effect of empagliflozin on carotid (A) and aortic (B) augmentation indices during clamped euglycaemia and
hyperglycaemia in patients with type 1 diabetes. *p < 0.0001 compared to baseline parameter under the same glycemic condition.
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generally safe and well tolerated [22,34-39]. Our goal was
to further clarify the mechanistic basis for the blood pres-
sure lowering effect of empagliflozin, including effects on
arterial stiffness and neurohormonal activation measured
by heart rate variability, since both of these parameters are
associated with systemic blood pressure and correlate with
long-term renal and cardiovascular outcomes [5,40-42].
Our major novel finding was that empagliflozin reduced
measures of arterial stiffness under both clamped euglyce-
mic and hyperglycemic conditions. We also observed that
after treatment with empagliflozin for 8 weeks, systolic
blood pressure decreased significantly in normotensive pa-
tients with T1D.The effect of oral hypoglycemic agents on arterial
stiffness
Previous studies in T2D have suggested that oral
hypoglycemic agents such as metformin reduce blood
pressure, primarily through improving glycemic control
[12-14,43]. In contrast, other oral hypoglycemic agents
such as sulfonylureas that increase the risk of severe
hypoglycemic events and lead to body weight gain may
promote the development of hypertension [44]. Perhapsas a result of increasing weight, these traditional oral
hypoglycemic agents do not improve arterial stiffness pa-
rameters and a significant proportion of patients develop
hypertension with increasing diabetes duration [45,46].
Since existing oral agents are not approved nor appro-
priate in T1D, the options for improving glycemic con-
trol in patients with T1D are limited to intensifying
insulin regimens, which can have the same adverse ef-
fects on weight, hypoglycemic risk and blood pressure as
in T2D patients [30-32]. This study shows for the first
time that an oral hypoglycemic agent that improves gly-
cemic control over an 8-week period in patients with
T1D can also reduce arterial stiffness, which may in part
be responsible for the antihypertensive effects associated
with SGLT2 inhibition.Regulators of arterial stiffness
Arterial stiffness is influenced by a variety of factors, in-
cluding neurohormonal mediators and changes in arter-
ial structure [4]. We have previously demonstrated in
this cohort that empagliflozin induces a modest increase
in plasma RAAS mediators, including aldosterone and
angiotensin II, which is likely a compensatory response
to effective circulating volume contraction, similar to
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increase in plasma RAAS levels with empagliflozin was
insufficient to counteract the effect of effective circulat-
ing volume contraction, resulting in decreases in blood
pressure and arterial stiffness. A similar observation was
made for vasodilatory NO, for which we observed a de-
cline in plasma levels in our previous work, which was
also unlikely to have accounted for decreases in blood
pressure or arterial stiffness in this cohort [24]. We
therefore concluded that the beneficial hemodynamic
changes observed with empagliflozin were unlikely to be
influenced by concomitant changes in systemic RAAS
and NO activity. Consequently we hypothesized that im-
proved arterial compliance after empagliflozin could be
related to changes in autonomic nervous system func-
tion, reflected by increased HRV and lower circulating
levels of adrenaline and noradrenalin. However, empagli-
flozin did not affect HRV or plasma adrenergic system
markers, suggesting that the mechanisms responsible for
blood pressure and arterial stiffness lowering are inde-
pendent of effects on autonomic nervous system activity.
Nevertheless, our results do not exclude the possibility
that other neurohormonal factors related to hypergly-
caemia may have contributed to changes in blood pres-
sure and arterial stiffness, such as decreased reactive
oxygen species generation [48].
While neither RAAS, NO nor SNS activity can ex-
plain our results, we postulate that changes in arterial
stiffness with empagliflozin are due to several other fac-
tors (Figure 1). First, weight loss independently decreases
blood pressure and arterial stiffness [49]. Empagliflozin
was associated with a significant reduction in weight of
2.7 kg in our cohort and this may have contributed to
benefits on blood pressure and arterial stiffness, as previ-
ously reported [22,24]. This weight loss was likely in part
due to loss of fat, since waist circumference declined.
Second, decreases in daily insulin doses have been corre-
lated with improved arterial compliance in T2D, and a
similar interaction may have occurred in our T1D cohort
since total daily insulin doses decreased significantly by
the end of treatment [22,50]. Third, other diuretic agents
such as thiazides lower arterial stiffness and these effects
are likely in part due to direct effects on vascular smooth
muscle relaxation after induction of a negative sodium
balance [51,52]. Similar diuretic effects with SGLT2 in-
hibition may have contributed to the decline in arterial
stiffness in our cohort. Next, empagliflozin-induced
weight loss and improved glycemic control may exert anti-
inflammatory changes, which favour improvements in
blood pressure and arterial stiffness [49]. For example, in
experimental models of diabetes, SGLT2 inhibition reduces
oxidative stress and suppresses markers of inflammation
and fibrosis, including nuclear factor κβ and collagen IV
expression [53,54]. Due to the strong relationship betweeninflammation, cardiovascular complications and renal dis-
ease, future studies should clarify the ability of SGLT2 in-
hibitors to suppress inflammation in humans [55].
Arterial stiffness and long term clinical outcomes
Due to their insulin-independent mechanism of action
and as shown in animal models [56], SGLT2 inhibitors
have the potential to be used in T1D [22] in addition to
T2D [33]. Furthermore, SGLT2 inhibition may avoid
some of the most common treatment-related side effects
in T2D that have limited the benefits of traditional oral
hypoglycemic agents, including significant weight gain,
development and worsening of hypertension and severe
hypoglycemic events [33,39,57]. Our observations are, to
our knowledge, the first to suggest possible functional
benefits of an oral hypoglycemic agent on large vessel
function in T1D patients. The improvement in arterial
compliance is important because previous studies have
demonstrated strong, independent associations between
macrovascular complications and arterial stiffness in
T2D [58,59]. Increased arterial stiffness is also independ-
ently associated with clinically relevant outcomes in
T1D patients, including cardiovascular, renal, retinal and
autonomic complications [42]. Importantly, the benefi-
cial effects of conventional cardiovascular protective
agents such as ACE inhibitors have been in part attrib-
uted to improvements in arterial compliance [60]. Ul-
timately, large ongoing clinical outcomes trials in T2D
will determine if changes in arterial stiffness or blood
pressure with SGLT2 inhibition translate into long-term
renal or cardiovascular protection.
This trial has some limitations. First, the duration of
therapy was limited to 8 weeks. Therefore, conclusions
regarding longer term clinical benefits cannot be made
from this study. Second, further work is needed to ex-
plore the interdependence among beneficial effects on
arterial stiffness, including weight loss, glycemic control
and blood pressure seen with empagliflozin. In particu-
lar, we could not determine if changes in blood pressure
were based on declines in arterial stiffness, or whether
reduced arterial stiffness was responsible for the fall in
systolic blood pressure. Nevertheless, consistent changes
in these vascular parameters are encouraging and sup-
port the rationale for ongoing long-term cardiovascular
outcome trials. Third, these results in young patients
with uncomplicated T1D cannot be generalized to older
T1D patients, T1D patients with hypertension or to
those with T2D. Given the important relationship be-
tween age and arterial stiffness, future work should de-
termine if SGLT2 inhibition exerts similar effects in
older individuals. Finally, measures of arterial stiffness
have a high variability. As a consequence, our results
should be viewed as exploratory and should be con-
firmed in future studies.
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In summary, empagliflozin reduces arterial stiffness in
patients with T1D. Longer-term studies are warranted to
assess the safety and clinical effects of these agents in
T1D. Moreover, since arterial stiffness is a surrogate
marker for renal and cardiovascular clinical outcomes,
future trials should assess the effect of empagliflozin on
cardiorenal protection in patients with diabetes.
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